Table II.
Summary of Weight‐Adjusted Dose at Baseline and Blood Pressure Response in Phase 1
| Parameter | Obese Patients | Non‐Obese Patients | ||||
|---|---|---|---|---|---|---|
| Low Dose (n=57) | Medium Dose (n=30) | High Dose (n=53) | Low Dose (n=45) | Medium Dose (n=22) | High Dose (n=52) | |
| Baseline weight, kg | 86.2 (31.0) | 81.7 (33.4) | 87.5 (36.3) | 41.1 (16.0) | 43.1 (16.7) | 43.8 (17.5) |
| Baseline weight‐adjusted dose, mg/kg | 0.3 (0.1) | 1.1 (0.5) | 2.1 (0.8) | 0.5 (0.5) | 1.6 (0.3) | 3.2 (0.8) |
| Change in MSSBP, mm Hg | −7.1 (10.8) | −10.4 (9.8) | −10.3 (12.5) | −9.0 (9.9) | −8.6 (8.2) | −12.7 (9.6) |
| Change in MSDBP, mm Hg | −4.3 (11.2) | −7.0 (8.7) | −5.6 (9.1) | −5.0 (10.8) | −4.2 (9.0) | −9.2 (9.7) |
Values are expressed as means (standard deviation). Abbreviations: MSDBP, mean sitting diastolic blood pressure; MSSBP, mean sitting systolic blood pressure.